Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 4/20 | 0.36 |
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7142311 | 0.82 | TSHR (0.42) | CYP1A2TSHRMAOACES1CYP2A6 | |
| SCHEMBL8466227 | 0.78 | TSHR (0.50) | CYP1A2TSHRMAOACES1CYP2A6 | |
| SCHEMBL6645873 | 0.78 | MAOA (0.47) | CYP1A2MAOACES1CYP2A6MAOB | |
| SCHEMBL195129 | 0.73 | CYP1A2 (0.31) | CYP1A2 | |
| SCHEMBL312207 | 0.71 | ALOX15 (0.41) | AHRPDK2CA12CA9KMT2A | |
| SCHEMBL11897891 | 0.71 | OXTR (0.39) | CYP1A2TSHRMAOAMAOBKMT2A | |
| SCHEMBL1538761 | 0.69 | MAOA (0.43) | CYP1A2MAOACES1CYP2A6MAOB | |
| SCHEMBL10408023 | 0.69 | MAOA (0.35) | CYP1A2TSHRMAOACYP2A6MAOB | |
| SCHEMBL15529001 | 0.69 | TSHR (0.38) | CYP1A2TSHRMAOACES1MAOB | |
| SCHEMBL4728144 | 0.67 | MAOA (0.42) | CYP1A2TSHRMAOACES1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220009906-A1 | ISOINDOLIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-13 | — | — | US | claimed |
| US-4925777-A | Direct positives | FUJI PHOTO FILM CO., LTD. (JP) | 1990-05-15 | — | — | US | claimed |
| CN-118284692-A | Gene editing of PCSK9 or ANGPTL3 and compositions and methods of using same for treating diseases | 维乎医疗有限公司 | 2024-07-02 | — | — | CN | disclosed |
| WO-2024134657-A1 | PYRROLOPYRIDINE AND PYRROLOPYRIDAZINE BASED COMPOUNDS AND USE THEREOF AS PKR INHIBITORS | PROTEKT THERAPEUTICS LTD. (IL) | 2024-06-27 | — | — | WO | disclosed |
| US-20220009906-A1 | ISOINDOLIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-13 | — | — | US | disclosed |
| US-9187455-B2 | Substituted pyridazines as PDE10A inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2398795-B1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-10-15 | — | — | EP | disclosed |
| EP-2373641-B1 | PYRIDAZINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-8178538-B2 | Pyridazinones | HOFFMANN-LA ROCHE INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2398795-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-12-28 | — | — | EP | disclosed |
| EP-2373641-A1 | PYRIDAZINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010094762-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | disclosed |
| US-20100216793-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100152193-A1 | PYRIDAZINONES | HOFFMANN-LA ROCHE, INC. | 2010-06-17 | — | — | US | disclosed |
| WO-2010063610-A1 | PYRIDAZINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-10 | — | — | WO | disclosed |
| US-4925777-A | Direct positives | FUJI PHOTO FILM CO., LTD. (JP) | 1990-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152193-A1 | PYRIDAZINONES | PDE5A, PDE3A, PDE10A | CYP1A2 87/4885TSHR 902/4885MAOA 166/4885 |
| US-20220009906-A1 | ISOINDOLIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS | GRK2, GRK3, GRK4 | CYP1A2 1990/4885TSHR 3400/4885MAOA 3821/4885 |
| US-20100216793-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | PDE3A, PDE10A, PDE5A | CYP1A2 59/4885TSHR 761/4885MAOA 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.